A proven track record of value creation
We are a multinational pharmaceutical company with a local presence across North America and Canada, MENA and Europe, providing our customers with a broad range of generic, specialty and branded pharmaceutical products
Hikma released its Interim Results on 7 August 2025 for the six months ended 30 June 2025.
Recent results
Interim Results 2025
Khalid Nabilsi, CFO discusses our Interim Results performance
Learn more about Hikma
Our purpose is to put better health within reach, every day
Read about our progress
Annual Report
In 2024 we have continued to deliver on our mission to help shape a healthier world, and our leadership teams are advancing this agenda across our markets. We have been launching new products, signing partnerships, investing more into research and development, building new manufacturing plants, and deploying capital through acquisition to ensure we are well placed for continued growth.
Newsroom
All news stories
Latest news
- Hikma announces launch of Enoby™ (denosumab- qbde) and Xtrenbo™ (denosumab- qbde) referencing Prolia® and Xgeva® respectively Press Release, Product 19 January 2026 Hikma announces launch of Enoby™ (denosumab- qbde) and Xtrenbo™ (denosumab- qbde) referencing Prolia® and Xgeva® respectively
- Hikma achieves B scores in Climate Change and Water Security in 2025 CDP assessment Press Release, Corporate 15 January 2026 Hikma achieves B scores in Climate Change and Water Security in 2025 CDP assessment
- Hikma announces CEO change and Board appointment Press Release, Corporate 15 December 2025 Hikma announces CEO change and Board appointment
- Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US Press Release, Product 08 December 2025 Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US